KOWALIK, MARTA ANNA
 Distribuzione geografica
Continente #
EU - Europa 72.061
NA - Nord America 2.258
AS - Asia 400
AF - Africa 9
SA - Sud America 9
OC - Oceania 3
Totale 74.740
Nazione #
IT - Italia 71.440
US - Stati Uniti d'America 2.242
SE - Svezia 225
CN - Cina 219
UA - Ucraina 137
DE - Germania 101
SG - Singapore 56
GB - Regno Unito 54
FI - Finlandia 39
VN - Vietnam 28
TR - Turchia 27
IR - Iran 18
BE - Belgio 17
FR - Francia 17
KR - Corea 17
CA - Canada 15
IN - India 11
RU - Federazione Russa 8
MY - Malesia 7
ZA - Sudafrica 7
BR - Brasile 5
TW - Taiwan 5
CH - Svizzera 4
IL - Israele 4
MT - Malta 4
NL - Olanda 4
AU - Australia 3
IE - Irlanda 3
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
CO - Colombia 2
ES - Italia 2
PE - Perù 2
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
GR - Grecia 1
JP - Giappone 1
LT - Lituania 1
NG - Nigeria 1
NO - Norvegia 1
PA - Panama 1
PH - Filippine 1
SA - Arabia Saudita 1
Totale 74.740
Città #
Cagliari 71.244
Fairfield 311
Woodbridge 209
Chandler 193
Ashburn 179
Nyköping 175
Houston 154
Ann Arbor 143
Wilmington 113
Seattle 112
Cambridge 102
Dearborn 79
Jacksonville 61
Boardman 45
Shanghai 37
Beijing 31
Nanjing 29
Dong Ket 28
Redwood City 22
Helsinki 20
Singapore 20
Kocaeli 19
San Mateo 19
New York 18
Boston 17
Brussels 17
Milan 15
San Diego 15
Seoul 14
Toronto 13
Falls Church 12
Guangzhou 12
Los Angeles 12
Jiaxing 11
Mountain View 11
Rome 11
Nanchang 10
London 9
Shenyang 8
Bogazici 7
Changsha 7
Frankfurt am Main 7
Leawood 7
Auburn Hills 6
Augusta 6
Hefei 6
Milwaukee 6
Norwalk 6
Orange 6
Pune 6
Ardabil 5
Atlanta 5
Bari 5
Florence 5
Millbury 5
Phoenix 5
Ploaghe 5
Columbus 4
Hebei 4
Luras 4
Melita 4
Monmouth Junction 4
Monserrato 4
Pisa 4
Pretoria 4
Quartu Sant'elena 4
Sassari 4
Verona 4
Wuhan 4
Zhengzhou 4
Bologna 3
Curitiba 3
Dublin 3
Durban 3
Jinan 3
Livorno 3
Ningbo 3
Paris 3
Selargius 3
Shenzhen 3
Washington 3
Zurich 3
Azzano Decimo 2
Bayan Lepas 2
Bergamo 2
Bogotá 2
Chicago 2
Clauzetto 2
Kilburn 2
Kunming 2
Lambeth 2
Lerici 2
Lima 2
Nuoro 2
Palermo 2
Pasadena 2
Quanzhou 2
Quarrata 2
Saint-Fons 2
Salvador 2
Totale 73.779
Nome #
Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype 4.024
Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats 3.588
Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats 3.492
Statistical health monitoring applied to a metabolomic study of experimental hepatocarcinogenesis: an alternative approach to supervised methods for the identification of false positives 3.457
TRbeta is the critical thyroid hormone receptor isoform in T3-induced proliferation of hepatocytes and pancreatic acinar cells 3.417
Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis 3.400
Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice 3.394
Expression of c-jun is not mandatory for mouse hepatocyte proliferation induced by two nuclear receptor ligands: TCPOBOP and T3 3.387
YAP activation is an early event and a potential therapeutic target in liver cancer development 3.321
Global gene expression profile of normal and regenerating liver in young and old mice 3.269
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis 2.939
Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis 2.869
Transcription profiling by array of mouse liver from TCPOBOP treated wild type and c-jun conditional knockout animals. 2.852
Induction of autophagy promotes the growth of early preneoplastic rat liver nodules 2.811
MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). 2.785
Reply to: "YAP in tumorigenesis: Friend or foe?" 2.596
Emerging role of the pentose phosphate pathway in hepatocellular carcinoma 2.363
High frequency of β-catenin mutations in mouse hepatocellular carcinomas induced by a nongenotoxic constitutive androstane receptor agonist 2.324
Reply to: Clinical correlation of miR-375 and alpha-fetoprotein in hepatocellular carcinoma: comparison in mice and humans 2.159
Thyroid hormones, thyromimetics and their metabolites in the treatment of liver disease 2.098
Gender-specific interplay of signaling through β-catenin and CAR in the regulation of xenobiotic-induced hepatocyte proliferation 1.764
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience 1.597
Early metabolic changes in a liver carcinogenesis model 1.061
Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection 939
Early Metabolic Changes in preneoplastc nodules of the liver 927
Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming 796
Animal models: A useful tool to unveil metabolic changes in hepatocellular carcinoma 713
Potential role of two novel agonists of thyroid hormone receptor-β on liver regeneration 694
Effect of the ligands of thyroid hormone receptor on non-alcoholic fatty liver disease 681
Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis 674
Nrf2 Mutation/Activation Is Dispensable for the Development of Chemically Induced Mouse HCC 577
Tg68, a novel thyroid hormone receptor‐β agonist for the treatment of NAFLD 424
The double-sided of human leukocyte antigen-G molecules in type 1 autoimmune hepatitis 379
mRNA-miRNA networks identify metabolic pathways associated to the anti-tumorigenic effect of thyroid hormone on preneoplastic nodules and hepatocellular carcinoma 359
Distinct Mechanisms Are Responsible for Nrf2-Keap1 Pathway Activation at Different Stages of Rat Hepatocarcinogenesis 277
Diverse MicroRNAs-mRNA networks regulate the priming phase of mouse liver regeneration and of direct hyperplasia 266
Delta-globin gene expression improves sickle cell disease in a humanised mouse model 265
Characterization Of Early Stage Metabolic Perturbations In A Rat Model Of Hepatocellular Carcinogenesis 258
Novel thyroid hormone receptor-beta agonist TG68 safely induces hepatic fat reduction in a non-alcoholic steatohepatitis rat model 231
Novel thyroid hormone receptor-beta agonist TG68 safely induces hepatic fat reduction in a non-alcoholic steatohepatitis rat model 229
Novel thyroid hormone receptor beta agonist TG68 safely induces hepatic fat loss reduction in a NASH mouse model 218
THYROID HORMONE INHIBITS HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT BY INTERFERING WITH THE METABOLIC PROFILE OF CANCER CELLS 216
Novel thyroid hormone receptor-beta agonist TG68 safely induces hepatic fat reduction in a non-alcoholic steatohepatitis rat model 215
The density of hepatic autonomic innervation differs between compensatory and direct hyperplasia rat models 211
Multi-Organ Morphological Findings in a Humanized Murine Model of Sickle Cell Trait 159
Potential use of TG68 - A novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis 97
Sex difference in liver diseases: How preclinical models help to dissect the sex-related mechanisms sustaining NAFLD and hepatocellular carcinoma 75
Metabolic reprogramming in Nrf2-driven proliferation of normal rat hepatocytes 53
Totale 74.900
Categoria #
all - tutte 86.954
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.954


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202014.442 590 507 51 129 5.221 3.742 1.983 450 262 355 386 766
2020/202118.781 532 816 733 5.573 3.262 2.004 1.248 1.166 596 1.123 1.138 590
2021/20225.241 755 347 229 341 512 363 208 190 536 571 598 591
2022/20237.832 448 870 1.016 693 625 876 502 456 520 643 777 406
2023/20247.534 471 248 273 381 723 1.152 1.307 683 349 443 635 869
2024/20251.718 1.718 0 0 0 0 0 0 0 0 0 0 0
Totale 74.900